Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

LifeVantage Corporation Plans to Initiate a Self-Tender Offer for Up to $40,000,000 of Its Common Stock



LifeVantage Corporation Plans to Initiate a Self-Tender Offer for Up to
$40,000,000 of Its Common Stock

SALT LAKE CITY, Sept. 12, 2013 (GLOBE NEWSWIRE) -- LifeVantage Corporation
(Nasdaq:LFVN), a company dedicated to helping people achieve healthy living
through a combination of a compelling business opportunity and scientifically
validated products, announced today that it intends to conduct a modified
Dutch auction self-tender offer to repurchase up to $40,000,000 of its common
stock at a price per share within a range to be determined prior to
commencement of the tender offer. A modified Dutch auction tender offer allows
shareholders to indicate how many shares and at what price within the
Company's specified range they wish to tender. Based on the number of shares
tendered and the prices specified by the tendering shareholders, the Company
will determine the lowest price per share within the range that will enable
the Company to purchase $40,000,000 of its common stock, or a lesser amount if
the offer is not fully subscribed. All shares repurchased by the Company in
the tender offer will be purchased at the same price. The Company expects to
enter into a new credit facility to fund the share purchases in the tender
offer.

LifeVantage currently anticipates commencing the tender offer on or about
September 24, 2013, but intends to make a further announcement prior to
commencing the tender offer. The tender offer will be held open for at least
twenty business days following its commencement, and tenders of shares must be
made prior to the expiration of the tender offer period.

Shareholders will be able to obtain copies of the offer to purchase, related
materials filed by the Company as part of the statement on Schedule TO and
other documents filed with the Securities and Exchange Commission through the
SEC's website at www.sec.gov without charge when these documents become
available. Shareholders may also obtain a copy of these documents, as well as
any other documents the Company has filed with the SEC, without charge, by
contacting the Company or through the Company's website at
www.lifevantage.com. Shareholders are urged to carefully read these materials,
when available, prior to making any decision with respect to the offer.

Tender Offer Statement

The anticipated tender offer discussed in this press release has not yet
commenced. This press release is for informational purposes only and is
neither an offer to purchase nor a solicitation of an offer to sell any shares
of the Company's common stock. The solicitation and offer to buy the Company's
common stock will only be made pursuant to the offer to purchase and related
materials that the Company will make available to its shareholders.
Shareholders should read those materials and the documents incorporated
therein by reference carefully when they become available because they will
contain important information, including the various terms and conditions of
the tender offer.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq:LFVN), a leader in Nrf2 science and the maker
of Protandim®, the Nrf2 Synergizer® patented dietary supplement, TrueScience®
Anti-Aging Cream and LifeVantage® Canine Health, is a science based network
marketing company. LifeVantage is dedicated to visionary science that looks to
transform wellness and anti-aging internally and externally with products that
dramatically reduce oxidative stress at the cellular level. LifeVantage was
founded in 2003 and is headquartered in Salt Lake City, Utah.

Forward Looking Statements

This press release contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Words and expressions reflecting optimism, satisfaction or
disappointment with current prospects, as well as words such as "believe,"
"hopes," "intends," "estimates," "expects," "projects," "plans,"
"anticipates," "look forward to" and variations thereof, identify
forward-looking statements, but their absence does not mean that a statement
is not forward-looking. Examples of forward-looking statements in this press
release include, but are not limited to, statements about LifeVantage's plans
and strategies relating to the anticipated tender offer and LifeVantage's
ability to secure a new credit facility. Such forward-looking statements are
not guarantees of performance and LifeVantage's actual results could differ
materially from those contained in such statements. These forward-looking
statements are based on LifeVantage's current expectations and beliefs
concerning future events affecting LifeVantage and involve known and unknown
risks and uncertainties that may cause LifeVantage's actual results or
outcomes to be materially different from those anticipated and discussed
herein. These risks and uncertainties include, among others, the Company's
inability to successfully expand its operations; the Company's inability to
conform to government regulations in existing markets; the Company may not
succeed in growing existing markets or opening new international markets; the
Company may be unable to effectively manage its growth; the Company may
experience disruptions in its information technology systems; the Company may
become subject to claims as a result of its independent distributors failing
to comply with its policies and procedures; if the Company introduces new
products, those new products may not gain distributor or market acceptance;
the Company may be adversely affected by international trade or foreign
exchange restrictions, increased tariffs, foreign currency exchange; global
economic conditions could deteriorate and affect the Company; the Company's
significant dependence on a single product may adversely affect the Company;
the Company may be unable to obtain high quality raw materials for its
products; the Company may be unable to retain independent distributors or to
attract new independent distributors on an ongoing basis; the Company may
become subject to a product recall; the Company's dependence on third party
manufacturers; the Company's network marketing activities are heavily
regulated and may become the subject of actions from third parties and
governmental agencies; the Company's direct selling program could be found to
not be in compliance with current or newly adopted laws or regulations; the
Company may become subject to unfavorable publicity; the Company may become
involved in expensive and time consuming legal proceedings; the Company may
become subject to an investigation or enforcement action by the federal trade
commission; the Company may lose key personnel; and the Company's inability to
protects its intellectual property. These and other risk factors are discussed
in greater detail in LifeVantage's Annual Report on Form 10-K under the
caption "Risk Factors," and in other documents filed by LifeVantage from time
to time with the SEC. LifeVantage cautions investors not to place undue
reliance on the forward-looking statements contained in this document. All
forward-looking statements are based on information currently available to
LifeVantage on the date hereof, and LifeVantage undertakes no obligation to
revise or update these forward-looking statements to reflect events or
circumstances after the date of this document, except as required by law.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement